Regulation & policy
- Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO – September/October 2024
18 Nov, 2024 - Bill Seeks Reimbursement For COVID Vaccine Injuries
16 Nov, 2024 - Implications of the apparent extinction of B/Yamagata-lineage human influenza viruses
16 Nov, 2024 - Maternal vaccination for preventing respiratory syncytial virus-associated disease in infants
15 Nov, 2024 - MHRA approves adapted Nuvaxovid JN.1 COVID-19 vaccines for adults and children aged 12 plus
15 Nov, 2024 - ‘It’s definitely in the community’ | CDC lowers age recommendation for pneumonia vaccine
15 Nov, 2024 - Covid vaccine eligibility set to shrink next year as disease become endemic
14 Nov, 2024 - Ministry proposes adding dengue vaccine in expanded immunisation programme
13 Nov, 2024 - JCVI backs reduced COVID-19 jab programme
13 Nov, 2024 - FDA clears investigational NDA for VAX-31 to prevent invasive pneumococcal disease
12 Nov, 2024 - Arcturus gains IND clearance for H5N1 influenza sa-RNA vaccine candidate
12 Nov, 2024 - Vaxcyte’s VAX-31 Vaccine Secures FDA Breakthrough Status, Targets 95% Disease Coverage | PCVX Stock News
12 Nov, 2024 - NACI Guidance on Influenza Vaccination in Adults 65 and Older, CCDR 50(11)
12 Nov, 2024 - Barriers to US suburban Mpox vaccination persist amidst global emergency
12 Nov, 2024 - Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs
12 Nov, 2024 - Prenatal Vaccines in Medicaid and CHIP: Current Reimbursement and Policies to Increase Access
11 Nov, 2024 - Impact of accelerated review policy on portfolio planning of vaccine companies
11 Nov, 2024
0 Comments